Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NetraMark Holdings ( (TSE:AIAI) ) just unveiled an announcement.
NetraMark has unveiled new findings showing that its NetraAI platform can identify treatment-responsive patient subgroups within the landmark A4 trial of solanezumab in asymptomatic Alzheimer’s disease. Presented at the AD/PD 2026 conference, the analysis uncovered two biologically interpretable responder groups with preserved neural reserve, where effect sizes reached up to Cohen’s d of 1.52.
These results highlight how patient heterogeneity can mask drug efficacy in large Alzheimer’s trials and suggest that AI-driven patient stratification could reveal therapeutic signals overlooked by traditional analyses. For drug developers, NetraAI’s explainable subgroup discovery points to a path for precision enrichment strategies, retrospective trial re-analysis, and potentially lower development risk and cost as the industry shifts toward earlier-stage, precision-guided Alzheimer’s therapies.
More about NetraMark Holdings
NetraMark Holdings Inc. is a Toronto-based company that develops advanced artificial intelligence solutions aimed at optimizing clinical trials and enabling precision medicine. Its proprietary explainable AI platform, NetraAI, is designed to analyze complex, multimodal patient data to identify interpretable subgroups, with a particular focus on improving drug development in areas such as Alzheimer’s disease.
Average Trading Volume: 48,286
Technical Sentiment Signal: Hold
Current Market Cap: C$91.83M
Learn more about AIAI stock on TipRanks’ Stock Analysis page.